Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05973630 · ClinicalTrials.gov registry record · Phase 1
ATA-200 Gene Therapy Trial in Patients With LGMDR5
A Phase 1 study of LGMD2C, sponsored by Atamyo Therapeutics.
- Active
- Registry status
- Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05973630 is a Phase 1 study of LGMD2C that is active but no longer recruiting, run by Atamyo Therapeutics. The registered enrollment target is 4 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05973630, a Phase 1 study of LGMD2C, is active but no longer recruiting, sponsored by Atamyo Therapeutics.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5).
Conditions Studied
Interventions
- BIOLOGICAL ATA-200
Study Locations (1)
Florida
- Child Health Research Institute - Gainsville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2025-02-15 |
| Est. Completion | 2031-01-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05973630
The ClinicalTrials.gov registry entry for NCT05973630 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Atamyo Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with LGMD2C appearing as the primary indexed condition, and to 1 intervention - of which ATA-200 is the first listed.
NCT05973630 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05973630 about?
NCT05973630 is a clinical study titled "ATA-200 Gene Therapy Trial in Patients With LGMDR5". The purpose of ATA-003-GSAR study is to evaluate the safety and tolerability of a single intravenous infusion of ATA-200 in pediatric patients with limb girdle muscular dystrophy type 2c/R5 (LGMD R5).
What is the current status of trial NCT05973630?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 4 participants. The study started on 2025-02-15. Estimated completion is 2031-01-31.
What conditions does trial NCT05973630 study?
This clinical trial studies the following conditions: LGMD2C.
What interventions are being tested in trial NCT05973630?
The interventions under investigation include: ATA-200 (BIOLOGICAL).
Who is sponsoring clinical trial NCT05973630?
This trial is sponsored by Atamyo Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05973630 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for LGMD2C
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.